

Report of the Chief Financial Officer

Finance Report – September 2012
(Month 06)

Date of meeting 29th October 2012





Contents

	Page
Executive Summary	3
Income & Expenditure Account	4
Financial Risk	5
Risks	6
Activity Performance Summary	7
Performance against SLA and Income Targets	8
Acute Performance against PCT Activity and Income Trends	9
Community Performance against PCT Activity and Income Trends	10
Performance against PCT Activity and Income Targets	11
Expenditure by Directorate	12
Expenditure Commentary	13
Expenditure Exception Report	14 - 19
Expenditure Budget Performance - Pay	20 - 21
CIP Monitoring – All Trust Schemes	22- 24
Reserves	25
Capital Expenditure	26 - 27
Statement of Financial Position	28
Trade Receivables	29 - 30
Trade, Other Payables and Borrowings	31
Statements of Cash Flows/ Cash Position against Plan	32
Charitable Funds	33

Executive Summary

- The Trusts Income and Expenditure position as at Month 6 is a surplus of £2,480, which is £271k below the month 6 plan. The detail can be found on page 4. This position is an improvement of £499k compared to last month.
- The Trust's operating position (Earnings before interest, taxation, depreciation and amortisation – EBITDA) is adverse to plan by (£331k) (2.2%).
- Total income at month 6 is £187,977k which is above plan by £2,794k. This builds in a contingency of £2,000k in respect of emergency readmissions and non elective threshold adjustments. Patient care contract income is showing an under performance of (£239k), details are on page 7. Directorate expenditure is adverse to plan by (£2,913k) and is analysed as follows:
 - Pay (£2,003k)
 - Non Pay (£883k)
 - Drugs (£27k)

Further details on Expenditure, performance against budget, are provided on pages 12 to 19. An analysis of Reserves is provided at page 25.

- The Divisions have now been set control totals to deliver the planned financial targets by year end. Monthly run rates are in place to monitor performance by Directorate.
- The Trust CIP target for 2012/13 is £15,325k. At month 6 £6,794k has been withdrawn from budgets, which represents 44% of the total. Pages 22 to 24 detail the CIP schemes. The level of performance is now a cause for concern and is being monitored closely by the Change Programme Board.

- Capital Spend for Month 6 was £2,485k below plan. Of this underspend circa £1million relates to the previously reported re-profile of the Combined Heat and Power, (CHP) scheme. The Head of Estates Development Report to the Board provides further information regarding the other areas of underspend and notes that a number of schemes are being considered for inclusion in a Revised Capital Programme. This will be agreed during October 2012 and on this basis, no risk is currently envisaged in achieving the year end CRL position. Full year Capital Programme Plan is £23,454k (excluding PFI/leases). Capital Resource Limit (CRL) is expected to be £25,195k including PFI (Radiology) £2,541k less (£800k) adjustment for sale of Old Eye Infirmary. Formal SHA notification has been received for £22,654k but CRL for PFI is expected later in the year, in line with normal practice. Further detail is provided on pages 26 and 27.
- The closing cash balance of £16,635k is in line with plan (prior year closing balance £15,658k). The Statement of Financial Position, working capital, cash flow, and details of the trade receivables and payables are shown on pages 28 to 32.
- Charitable Funds Summary providing the main movements for the second quarter are shown at page 33.
- Compliance Framework performance against Financial Risk Ratings is shown at Page 5. This shows a risk rating of 3.5, out of a possible 5.

Performance against Financial Targets

	Target	Performance	RAG
I & E Target Month 6	£2,750k	£2,480k	
CRL (Year end forecast, includes PFI related additions)	£25,195k	£25,195k	
EFL (Year end forecast)	0	(£3,571k)	
Capital Cost Absorption Rate (Year end)	3.50%	3.50%	



Income & Expenditure Account

Current Month Plan	Current Month Actual	Current Month Variance		Original Plan	Annual Budget	Plan to Date	Actual to Date	Variance to Date
£'000	£'000	£'000		£'000	£'000	£'000	£'000	£'000
			Income					
27,727	28,563	835.31	Patient Activity Income	337,624	344,858	170,764	170,524	(239)
(333)	0	333.33	Patient Activity Contingency **	(4,000)	(4,000)	(2,000)	0	2,000
89	76	(12.44)	Other Patient Care Income	1,640	1,064	532	503	(29)
1,085	1,044	(41.45)	Education, Training & Research Income	10,953	13,005	6,510	6,861	351
19	19	0.08	Non Patient Care Other Income	0	232	232	432	200
94	58	(36.52)	Private Patient Income	1,059	1,083	554	711	157
1,405	1,557	151.40	Income on Directorate Budgets	15,971	16,420	8,593	8,946	353
30,086	31,316	1,230	Total Income	363,247	372,662	185,184	187,977	2,794
			Expenditure					
(19,449)	(19,700)	(251)	Directorate Expenditure Budgets - Pay	(223,817)	(230,884)	(115,758)	(117,761)	(2,003)
(6,605)	(6,807)	(202)	Directorate Expenditure Budgets - Non Pay	(73,135)	(78,640)	(40,051)	(40,934)	(883)
(2,307)	(2,357)	(50)	Directorate Expenditure Budgets - Drugs	(22,922)	(27,196)	(14,643)	(14,670)	(27)
(105)	0	105	Activity Changes/Service Dev./Cost Pressures Reserves	(17,985)	(9,146)	(2,538)	0	2,538
(231)	0	231	Inflation and Contingency Reserves	(8,452)	(3,065)	(1,497)	0	1,497
554	0	(554)	Cost Improvement Savings - Current Year	15,325	8,531	4,245	0	(4,245)
(28,143)	(28,864)	(721)	Total Expenditure	(330,986)	(340,401)	(170,240)	(173,365)	(3,125)
1,944	2,452	509	EBITDA Surplus/(Deficit)	32,262	32,262	14,944	14,612	(331)
0	0	0	Profit/(Loss) on Asset Disposals	0	0	0	0	0
0	0	0	Impairments of Fixed Assets	(3,332)	(3,332)	0	0	0
(1,255)	(1,236)	18	Depreciation	(15,054)	(15,054)	(7,527)	(7,344)	183
8	8	(1)	Interest Receivable	100	100	50	50	(0)
(109)	(129)	(19)	Interest Payable	(1,313)	(1,313)	(656)	(771)	(115)
(677)	(684)	(7)	PDC Dividends (Cost of Capital)	(8,120)	(8,120)	(4,060)	(4,067)	(7)
0	0	0	Unwinding of Discount	0	0	0	0	0
(88)	411	500	Net Surplus/(Deficit)	4,543	4,543	2,750	2,480	(271)

** Reserve set at budget setting for reduced income due to tariff rules on emergency readmissions and non elective cap

Financial Risk

Financial Risk Rating						
Ratio KPIs	Annual Plan	Rating	Plan to Date	Actual to Date	Rating	Definitions
EBITDA Achieved	100.0 %	5	100.0 %	97.8 %	4	=EBITDA Actual/EBITDA Budget (both year to date)
EBITDA Margin	8.8 %	3	8.0 %	7.8 %	3	=EBITDA/Total Income
Net Return on Financing	3.1 %	5	3.1 %	3.2 % forecast	5	=(I&E Surplus less PDC dividend, Interest, PFI financing other finance lease costs)/divided by(total debt + balance sheetPFI & Finance leases+Taxpayers equity)
I & E Surplus Margin	2.1 %	4	1.5 %	1.3 %	3	=Net Surplus/(Deficit)/Total Income
Liquidity Ratio	24.1 Days	3	24.1 days	24.7 days	3	= prior year cash plus trade debtors less trade creditors plus working capital facility expressed as days of current year operating expenses
		3.8			Overall Rating	3.5



Potential financial risk indicators	Risk to RWH?	Action required
Unplanned decrease in EBITDA margin in two consecutive quarters	No	N/A
FRR 2 for any one quarter	No	N/A
Debtors > 90 days past due account for more than 5% of total debtor balances	No	N/A
Two or more changes in Finance Director in a twelve month period	No	N/A
Quarter end cash balance < 10 days of operating expenses	No	N/A
Quarterly self-certification by trust that the financial risk rating (FRR) may be less than 3 in the next 12 months	No	N/A
Working capital facility (WCF) agreement includes default clause	No	N/A
Creditors > 90 days past due account for more than 5% of total creditor balances	No	N/A
Interim Finance Director in place over more than one quarter end	No	N/A
Capital expenditure < 75% of plan for the year to date	No	N/A

Risks

The level of financial risk and mitigations have been assessed. The level of slippage and red risk against CIP schemes has been reviewed and replacement schemes put in place. The residual risk of £2.5m relates to schemes at risk of not being achieved and replacement schemes are being considered.

Risk	Likelihood of risk	Potential consequence rating	Risk	Current Forecast Risk £000's	Risk after Mitigation £000's	Risk After Mitigation	Mitigating Action
Cost Improvement Programme - underachievement of plans	Likely	Moderate	B3	3,777	2,540	B2	1. The projected slippage and red risk of £3.8m has been reviewed and some replacement schemes put in place. 2. There is a reported potential risk of £2.5m non achievement of schemes and replacement schemes are currently being considered for approval.
Contract income issues- Penalties, Readmissions, Emergency Threshold	Possible	Moderate	C3	3,980	0	C2	1. The forecast risk is based on current performance, systems are in place to alert when issues occur. 2. Discussions have been held with Commissioners to mitigate the impact of risks by ensuring that funds are utilised appropriately. 3. Reserves are held to mitigate against the risks.

Risk Rating				
Likelihood Rating	Potential Consequence Rating			
	1. Insignificant	2. Minor	3. Moderate	4 Major
A - Almost Certain	Yellow	Orange	Red	Dark Red
B - Likely	Yellow	Orange	Red	Dark Red
C - Possible	Green	Yellow	Orange	Red
D - Unlikely	Green	Yellow	Orange	Red
E - Rare	Green	Yellow	Orange	Red

Overall Rating
Low
Medium
High

SLA and Income: Actual vs. Plan by Specialty

The patient activity income as at month 6 is showing an underperformance of £239k, which is an improvement of £837k on the position at month 5.

Division	Specialty	Month 6 Variance £000	Month 6 Variance %	Month 5 Variance £000	Movement £000	Notes
Division 1	General Surgery	(573)	(5.3)	(378)	(195)	1
	Critical Care	(19)	(0.3)	(515)	496	2
	Drugs & Devices	(44)	(2.9)	(33)	(12)	
	Trauma & Orthopaedics	(968)	(7.6)	(887)	(80)	3
	Head and Neck	59	1.4	95	(36)	
	Ophthalmology	526	6.9	439	87	4
	Gynaecology	(386)	(9.8)	(347)	(39)	
	Obstetrics inc Scans	11	0.2	25	(14)	
	GP Direct Access	217	8.9	175	43	
	Urology	102	3.2	110	(9)	
Cardiothoracic/Cardiology		70	0.5	(18)	88	5
	Other	(721)	(25.5)	(599)	(122)	6
Total		(1,726)	(2.3)	(1,933)	207	
Division 2	General Medicine	1,348	7.7	1,200	148	7
	Clinical Haematology/Oncology	906	11.9	696	210	8
	Cystic Fibrosis	(32)	(7.7)	(23)	(9)	
	Drugs & Devices	48	1.5	35	13	
	Paediatrics	351	9.7	343	8	
	GP Direct Access	(1)	(0.1)	6	(7)	
	Nephrology and Dialysis	(468)	(7.2)	(482)	14	
	Accident & Emergency	444	8.3	368	77	9
	Other	(860)	(6.2)	(947)	87	10
	Total		1,736	3.0	1,197	539
Other	Drugs & Devices	0	0.0	0	0	
	Other	(266)	(23.1)	(250)	(16)	
Total		(266)	(4.4)	(250)	(16)	
Patient Activity as per SLAM		(256)	(0.2)	(985)	730	
NET 2011-12 underperformance		(205)		(85)	(120)	
Partially completed spells and other		145		(64)	209	11
Community Services		77		59	18	
Patient Activity Income		(239)		(1,075)	837	






- General Surgery** – Underperformance against planned activity levels has continued with an increase in non elective of £99k (-35spells), and £45k (-60 spells) non elective. However, performance is expected to improve later in the year.
- Critical Care** – The financial performance has improved with an agreed amendment to the charging method with Specialised Services.
- Trauma and Orthopaedics** – The under performance of 7.6% is an improvement on last month 8.4%, following the recruitment to a locum vacancy , and the inclusion of best practice tariff income for fragile hips that was previously shown against the “Other” category.
- Ophthalmology** - The favourable position for Ophthalmology continues to relate to planned same day attendances and first and follow up outpatient attendances, as a result of increased referrals.
- Cardiothoracic / Cardiology** - There has been an improvement in Cardiac Surgery of £41k (1 spell) and £24k (113 attendances) for Cardiology first outpatient attendances, where referrals are showing an upwards trend.
- Other (Division 1)** – Of the in month adverse movement £78k relates to the transfer of best practice tariff income to the Trauma and Orthopaedics, as noted above.
- General Medicine** - Non elective activity continues to be the main driver of over-performance, 259 spells and continues to reflect the pressures felt within the hospital.
- Clinical Haematology/Oncology** - The favourable movement of £210k is due to increased day case activity mainly associated with the administration of drugs for treatment of cancer.
- Accident & Emergency** –The high levels of activity previously reported have continued in month, with 5% (2393 attendances).
- Other (Division 2)** - Of the in month movement £74k relates to an increase in Radiotherapy Fractions (710 fractions above September plan). The growth is in line with the Directorates expectations and is due to increased demand.
- Partially Completed Spells and Other** – Of the movement £196k is due to an increase in partially completed spells.

SLA and Income: Actual vs. Plan by POD*




Admission Type	Annual Plan	Variance To Date	% Variance	Annual Price Plan	Variance To Date £	% Variance
				£000	£000	%
Accident and Emergency	102,463	2,393	2.34%	9,624	507	5.27%
Critical Care	20,110	(462)	-2.30%	16,281	(327)	-2.01%
Elective	45,012	843	1.87%	58,027	289	0.50%
Elective Excess Bed Days	2,603	(63)	-2.43%	613	(17)	-2.82%
Direct Access	534,799	8,187	1.53%	4,880	217	4.45%
Non-elective	46,077	365	0.79%	78,785	964	1.22%
Non-elective Excess Bed Days	16,200	(594)	-3.67%	3,821	(158)	-4.12%
Outpatient First	120,836	5,728	4.74%	18,341	1,000	5.45%
Outpatient Follow Up	330,715	5,477	1.66%	26,779	317	1.18%
Outpatient Procedures	37,114	(297)	-0.80%	6,344	(36)	-0.56%
Renal	87,070	(3,557)	-4.09%	9,568	(237)	-2.48%
Fractions	32,359	710	2.19%	7,836	173	2.21%
Drugs/Devices	3,756	(448)	-11.92%	18,738	(9)	-0.05%
Other	27,652	(221)	-0.80%	20,685	(2,938)	-14.20%
Grand Total	1,406,765	18,060	1.28%	280,322	(256)	-0.09%

*POD = Points of Delivery

Performance against PCT Activity and Income trends



Community Performance against PCT Activity and Income trends



For Community Contacts the variance against FY1112 activity is misleading as there has been a change in measurement in FY1213.

SLA and Income: Actual versus Plan by PCT

The table shows the position in relation to Commissioner plans as at the end of month 6. The overall income is £179k (0.11%) below plan, with an overperformance of £2,346k (2.2%), against the PCT contracts, and a marginal overperformance against the specialised services contract of £78k (0.3%). This is offset by an underperformance of £2,632k against anticipated income. Anticipated income relates to vascular activity, for which actual activity is attributed to the specialised services contract and pass through costs such as drugs and devices. The overperformance against the community contract is attributable to Dudley and South Staffordshire PCT's.

	SLA Annual Plan	Plan to Date	Actual to date	Variance to Plan	% Variance
Commissioner	£000	£000	£000	£000	
South Birmingham	135	67	80	13	19.0%
Shropshire	4,201	2,090	2,012	(77)	-3.7%
Walsall	20,765	10,309	10,107	(201)	-2.0%
Telford	1,541	768	786	18	2.4%
Wolverhampton City	144,755	71,757	72,934	1,176	1.6%
Heart of Birmingham	143	71	108	37	51.5%
Dudley	8,310	4,129	4,394	265	6.4%
Sandwell	2,240	1,114	1,061	(53)	-4.7%
Birmingham East and North	286	142	109	(33)	-23.2%
North Staffs	28	14	25	11	78.7%
Stoke	80	40	49	10	25.0%
South Staffs	33,479	16,598	17,803	1,205	7.3%
Worcester	923	458	434	(25)	-5.4%
Acute Services Total	216,887	107,557	109,903	2,346	2.2%
Anticipated Income	3,605	2,632	0	(2,632)	-100.0%
Specialised Services	57,869	28,924	29,002	78	0.3%
NCA	1,961	973	926	(47)	-4.8%
Sub Total	280,322	140,086	139,831	(256)	-0.2%
Community Services	53,355	26,437	26,514	77	0.29%
Overall income	333,677	166,523	166,345	-179	-0.11%

Expenditure by Directorate

Trust Wide Summary

(£503k) overspend in month, (£2914k) overspend ytd

	Manpower WTEs This Month			VARIANCES Cumulative Against Budget											Patient income against budget		Expenditure variance Previous Month		Income Variance Previous Month	
				Pay		Non Pay		Drugs		Total (pre CIP)		CIP	Total (incl CIP)							
	Budget	Actual	% var	£'000	%	£'000	%	£'000	%	£'000	%	£'000	£'000	%	£'000	%	£'000	%	£'000	%
	Division 1	2,120	2,084	1.7%	(1,273)	(2.7%)	(672)	(4.2%)	226	6.5%	(1,719)	(2.6%)	(1,745)	(3,463)	(5.3%)	(1,726)	(2.3%)	(2,957)	(5.5%)	(1,933)
Division 2	2,456	2,448	0.3%	(1,175)	(2.4%)	(102)	(1.2%)	(248)	(2.2%)	(1,525)	(2.2%)	(1,576)	(3,101)	(4.7%)	1,736	3.0%	(2,609)	(4.7%)	1,197	2.4%
Estates and Facilities	616	602	2.4%	140	1.8%	94	1.5%	(16)		219	1.5%	(770)	(552)	(4.1%)			(394)	(3.4%)		
Chief Operating Officer	5	5	4.2%	2	0.8%	19	96.5%	0		21	7.6%	(0)	21	7.6%			17	7.5%		
Total Operations Directorate	5,198	5,138	1.1%	(2,306)	(2.2%)	(660)	(2.1%)	(37)	(0.3%)	(3,004)	(2.0%)	(4,091)	(7,095)	(4.9%)	10	0.7%	(5,943)	(4.9%)	(736)	(0.7%)
Corporate Directorates & Other	766	710	7.3%	303	2.5%	(223)	(2.5%)	10	38.0%	90	0.6%	(154)	(64)	(0.3%)	(266)	(4.4%)	(159)	(0.9%)	(250)	(4.9%)
Total Directorate Expenditure	5,964	5,848	1.9%	(2,003)	(1.7%)	(883)	(2.1%)	(27)	(0.2%)	(2,914)	(1.7%)	(4,245)	(7,159)	(4.3%)	(256)	(0.8%)	(6,102)	(4.3%)	(986)	(0.8%)

Monthly Manpower Figures in WTEs:-	Budget	Actual
April	5,965	5,877
May	6,002	5,788
June	5,984	5,800
July	5,982	5,804
August	5,987	5,820
September	5,964	5,848
October		
November		
December		
January		
February		
March		

Note: Wte's are now adjusted to reflect vacancy factor

Memorandum: Net Trading Position (Income and Cost)				
	This Month		Last Month	
	Pre CIP	Post CIP	Pre CIP	Post CIP
	£'000	£'000	£'000	£'000
Division 1	(3,445)	(5,189)	(3,386)	(4,890)
Division 2	211	(1,365)	21	(1,412)
	(3,234)	(6,554)	(3,365)	(6,302)

Expenditure Commentary

Trust Wide Summary

(£503k) overspend in month, (£2914k) overspend ytd

- The expenditure exception report on pages 13 to 23 provide details on the main areas of adverse movement. An exception is defined as an adverse monthly movement of £100k or more and/or 10%, but above a minimum of £20k.

Total Operations Expenditure

- The pay overspend includes overspends for Division 1 (£1,273k) and Division 2 (£1,175k) being slightly offset by an under spend in Estates & Facilities of £140k and COO is under spent by £2k. Division 1 over spend relates to the use of Waiting List Initiatives to meet Referral To Treatment targets in Orthopaedics, Cardiothoracic Surgery and to address the outpatient backlog in Ophthalmology, along with Nurse Bank usage covering sickness and maternity leave. The Division 2 overspend reflects costs of additional bed capacity, The Division is also experiencing cost pressures due to long term sickness issues which are currently being backfilled with agency staff and on the wards due to use of nurse bank covering vacancies, maternity leave and sickness.
- On non pay, Division 1 is over spent by (£672k) this is caused mainly due to increased diagnostic examinations in Radiology along with case mix in Cardiology, Orthopaedics and Head and Neck. These over spends are offset by underspends in Community Head and Neck and Ophthalmology. The non pay position in Division 2 shows an over spend of (£102k), this reflects the activity over performance being reported by the Division, the main areas overspending are Paediatrics, A&E and Emergency Groups. Estates & Facilities are under spent by £94k and COO is under spent by £19k.
- The drugs overspend relates to £226k in Division 1, (£248k) in Division 2 and (£16k) in Estates & Facilities.
- The Divisions have now been set control totals to deliver planned financial targets by year end.

Total Corporate and trading accounts

- The pay under spend is due to vacancies across several directorates
- The non-pay under spend mainly relates to the Trading Accounts which is off set by income.
- Further details and actions are on the following pages.

Operations Divisions Expenditure

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(1,969)	(2,306)	(338)	(2.23%)
Non pay	(426)	(660)	(234)	(2.11%)
Drugs	13	(37)	(51)	(0.26%)
Total	(2,382)	(3,004)	(622)	(2.01%)

Corporate and Trading Accounts Expenditure

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	217	303	87	2.45%
Non pay	(255)	(223)	32	(2.53%)
Drugs	10	10	1	38.00%
Total	(29)	90	119	0.05%

Total	(2,411)	(2,914)	(503)	(1.71%)
--------------	----------------	----------------	--------------	----------------

Expenditure Exception Report

Total Operational Directorate

(£622k) overspend in month, (£3004k) overspend ytd

Division 1

(£265k) overspend in month, (£1719k) overspend ytd

Both the month only and year to date variances of Division 1 are made up of a number of smaller variances spread across several directorates.

▪ Cardiology

Current Position

- The non pay overspend can be attributed to increased heart valve activity in Month, £99k, for which corresponding income will be reflected in SLAM. The overspend in this area is partially offset by lower ICD activity.

Actions

- The Directorate have planned to balance their budgets by the end of the year and this is included within the divisional control total target.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	13	17	4	0.4%
Non Pay	55	(23)	(77)	(1.1%)
Drugs	(0)	(0)	0	(7.3%)
Total	67	(6)	(73)	(0.1%)

▪ Pathology

Current Position

- The increase in month mainly relates to the number and complexity of tests being undertaken for both internal referrers and GP's.
- There was also an increase in month of £13k relating to seven Haemophilia patients, offset by in month contract income.

Actions

- Haemophilia activity is monitored rigorously in terms of blood product usage to ensure costs continue to be recovered from commissioners.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(73)	(83)	(11)	(2.6%)
Non Pay	(74)	(137)	(63)	(5.3%)
Drugs	19	19	(0)	6.2%
Total	(128)	(202)	(74)	(3.3%)

Division 1

(£265k) overspend in month, (£1719k) overspend ytd

▪ Ophthalmology

Current Position

- The underspend on drugs is a result in the price reduction for Lucentis.

Actions

- A price for Lucentis activity is separately agreed with Commissioners. It is likely that this underspend will have to be returned to the PCT as the local price for this activity will be renegotiated

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(170)	(215)	(45)	(5.7%)
Non Pay	49	37	(13)	5.5%
Drugs	157	194	37	10.5%
Total	37	16	(21)	0.3%

▪ Orthopaedics

Current Position

- The non pay overspend was largely seen in Orthotics where costs of patient appliances accounted for £18k of the overspend due to increased activity levels within the department.
- A further £8k was due to increased theatre costs as a result of additional sessions undertaken to meet RTT targets. Ward consumables resulting from increased activity were £7k overspent in month, predominantly due to the number of patients requiring VAC Therapy.

Actions

- The Divisional Management team are closely monitoring the Directorate recovery plan which brings the Directorate to a more favourable position in terms of income and expenditure.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(126)	(99)	28	(2.8%)
Non Pay	(85)	(117)	(32)	(6.0%)
Drugs	5	6	1	4.9%
Total	(206)	(210)	(4)	(3.7%)

Division 1

(£265k) overspend in month, (£1719k) overspend ytd

▪ **Head & Neck (Community)**

Current Position

- The under spend was seen mainly in Audiology where costs relating to the purchase and maintenance of hearing aids and moulds was below plan linked to patient activity, with a corresponding reduction in contract income.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	93	114	21	6.8%
Non Pay	96	123	27	54.9%
Drugs	1	1	0	57.3%
Total	190	239	48	12.6%

Division 2

(£349k) overspend in month, (£1525k) overspend ytd

▪ Divisional Management

Current Position

- The over spend against pay budgets reflects the cost of maintaining additional bed capacity to manage the increase in demand that the Division is currently experiencing, which is reflected in over performance in contract income.

Actions

- Additional capacity is reviewed and flexed with demand. Increased spending to be managed within the agreed allocation and total funding for the Division.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(314)	(407)	(94)	(22.0%)
Non Pay	(30)	(30)	(0)	(10.1%)
Drugs	(40)	(47)	(7)	
Total	(383)	(484)	(101)	(22.6%)

▪ Dermatology

Current Position

- The pay overspend is due to additional payments to consultants for clinics to accommodate community activity.

Actions

- The non recurrent costs of providing additional activity is currently being negotiated with commissioners. The level of increased payments to be reviewed within the directorate.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(145)	(181)	(35)	(40.0%)
Non Pay	0	1	1	3.5%
Drugs	22	26	4	16.1%
Total	(123)	(154)	(31)	(24.4%)

Division 2

(£349k) overspend in month, (£1525k) overspend ytd

Rehabilitation

Current Position

- The pay overspend relates to the use to agency staffing to cover junior doctor long term sickness.

Actions

- The member of staff has returned to work in October on a phased basis.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(121)	(150)	(28)	(4.4%)
Non Pay	27	5	(22)	0.6%
Drugs	(5)	(13)	(8)	(9.4%)
Total	(99)	(157)	(58)	(3.6%)

Clinical Haematology

Current Position

- The pay overspend in month relates to use of agency medical consultant to cover long term sickness within the department.

Actions

- It is planned to use the agency consultant until the end of October allowing a phased return to work for the staff member.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(84)	(113)	(29)	(8.8%)
Non Pay	9	28	19	6.4%
Drugs	7	(12)	(19)	(0.6%)
Total	(68)	(97)	(29)	(2.7%)

Division 2

(£349k) overspend in month, (£1525k) overspend ytd

▪ Paediatrics

Current Position

- The overspend on non pay is being driven by increases in activity levels and this impacting on both blood product expenditure and medical and surgical consumables.

Actions

- The group is over performing in non elective admissions and outpatient attendances generating increased income to the Trust.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(4)	18	22	0.4%
Non Pay	(74)	(82)	(9)	(29.0%)
Drugs	(19)	(58)	(39)	(15.7%)
Total	(96)	(122)	(26)	(2.4%)

▪ Stroke

Current Position

- The main reason for the pay overspend is agency usages to backfill vacancies and annual leave.

Actions

- This is under review with the Division and included within the control total to be delivered.

	YTD Variances £000			YTD % Var
	Month 5	Month 6	Movement	
Pay	(28)	(55)	(27)	(5.9%)
Non Pay	(5)	(5)	(0)	(10.3%)
Drugs	(19)	(23)	(4)	(46.6%)
Total	(51)	(82)	(31)	(8.1%)

Pay Reporting

Budget and worked WTE include agency, locum and bank staff. The below table shows the ytd WTE variance by division together with an analysis of ytd pay costs by division.

	Budget WTE	Actual Paid WTE	Pay (Over)/Under £000s	Pay Spend by Category (cumulative to date £000s)						Total Pay
				Agency	Medical Locums	Bank	Employed	Overtime	WLI	
Division 1	2,120	2,084	(1,273)	492	296	579	45,866	547	602	48,383
Division 2	2,456	2,448	(1,175)	1,819	664	1,162	45,265	413	7	49,331
Facilities & Estates	616	602	140	6	0	434	6,882	412	0	7,734
Chief Operating Officer	5	5	2	0	0	0	256	0	0	256
Total Operations Directorate	5,198	5,138	(2,306)	2,317	960	2,176	98,269	1,372	609	105,704
Corporate Directorate & Other	766	710	303	533	0	(33)	11,387	170	0	12,057
Total Directorate Pay Expenditure	5,964	5,848	(2,003)	2,850	960	2,142	109,657	1,542	609	117,761

- Division 1 – Overall Division 1 has a positive variance on WTE of 36 WTE. However, this has not resulted in savings. The key reasons for the overspend are a) agency and bank usage; and b) Waiting List Initiatives which do not attract WTE.
- Overall Division 2 has a positive manpower variance of 32 WTE. However, pay is over spending in total due to the additional costs of using agency, locums, bank staff and payments for overtime.

Agency / Locum / Bank Spend

	CURRENT YEAR		PREVIOUS YEAR			
	YTD Spend 12/13		YTD Spend 11/12		Total Spend 11/12	
	£000s	£000s	£000s	£000s	£000s	£000s
	Bank	Agency	Bank	Agency	Bank	Agency
Medical	33	2,049		1,390		3,117
Nursing - qual	977	48	909	2	1,905	19
Nursing - other	694		708		1,444	
PAMS	(1)					
Scientific & technical		260		213		482
Non-clinical	439	493	452	330	834	860
Total	2,142	2,850	2,069	1,935	4,183	4,478

Analysis of Agency in Non Clinical

	Current Year £000s	Last Year £000s
Operations		
Division 1	17	10
Division 2	41	3
Community Services		
Estates & Facilities	1	1
Chief Operating Officer		
Sub-total	59	15
Corporate		
Chief Executive	87	
Finance Director	296	245
Nurse Director	0	2
Medical Director	0	36
HR		(7)
Estates Development	5	6
R&D	47	33
Sub-total	434	315
Total Non-Clinical agency	493	330

Finance Director
£70k of the £296k current year agency costs has been recharged out to the PCT.

Pay reporting

Budget and worked WTE include agency, locum and bank staff. The table below takes the current WTE Actual (worked) vs budget for the month and analyses this by category (employed, overtime, agency, locum etc.) together with the month and ytd spend and compares this to the same month last year.

Pay Category	CURRENT YEAR 2012/13				LAST YEAR 2011/12				% YTD Month 6 Spend Increase Between Years
	WTE Budget in Month	WTE Actual (Worked) in Month	Current Month Spend £000	YTD Spend £000	Average Worked WTE	Month 6 Spend £000	YTD Spend to Month 6 £000	Average Monthly Spend £000	
Employed	5,940	5,655	18,361	109,657	5,591	17,961	106,989	17,908	2%
Overtime	0	4	266	1,542	(0)	204	1,309	226	18%
Agency Staff	15	37	408	2,850	44	275	1,935	373	47%
Medical Locum Staff	5	12	166	960	17	192	1,418	208	-32%
Bank	4	141	418	2,142	122	421	2,102	352	2%
WLI	0	0	82	609	0	76	373	65	63%
Total	5,964	5,848	19,700	117,761	5,775	19,128	114,124	19,131	3%

CIP Monitoring All Trust Schemes

The Trust CIP target is £15,325k. The table below summarises the target CIP for each Division and the actual achieved. The position for September shows a withdrawal of CIP from annual budget of £6,794 representing 44% of the total.

CIP MONITORING	2012/13					
	Annual Plan	Blue (withdrawn from budgets)	Still to be achieved			
			Categorised by Risk Rating			
2012/13 Schemes	£000	£000	Total £000	Green £000	Amber £000	Red £000
Estates & Facilities	2,252	591	1,661	(18)	685	995
Division 1	4,913	1,399	3,514	0	3,130	383
Division 2	5,838	2,787	3,051	156	2,707	188
Corporate	2,322	2,017	305	0	151	154
Trust Wide	0	0	0	0	0	0
Total 2012/13 Schemes	15,325	6,794	8,531	138	6,673	1,720

Non recurrent element withdrawn from budget
£000
128
488
49
418
0
1,083

Notes:
RAG Status
Blue = achieved.
Green = Ontrack to achieve
Amber = Some delay in achieving
Red = Significant delay / risk / detailed plan to be


Memorandum - Procurement CIP included in above table

	Annual Plan	Blue (withdrawn from budgets)	Still to be achieved			
			Total	Green	Amber	Red
2012/13 Schemes	1,347	696	651	0	651	0
Total Procurement CIP	1,347	696	651	0	651	0

12
12


CIP Monitoring by Division

	CIP Target	Current Year Actual	Actual Recurrent
Corporate	£2,321,930	£2,017,263	£1,589,118
Division 1 - Surgical	£4,913,185	£1,399,350	£921,927
Division 2 Medicine	£5,837,865	£2,786,907	£2,737,431
Estates and Facilities	£2,252,020	£590,548	£462,408
	£15,325,000	£6,794,068	£5,710,884



CIP Risks and Programme Status

Financial Risk Summary	Red	Amber	Green	Cleared	Total
Corporate	£154,162	£150,505	£0	£2,017,263	£2,321,930
Division 1 - Surgical	£383,430	£3,130,405	£0	£1,399,350	£4,913,185
Division 2 Medicine	£188,000	£2,707,151	£155,807	£2,786,907	£5,837,865
Estates and Facilities	£994,564	£684,608	-£17,700	£590,548	£2,252,020
Totals	£1,720,156	£6,672,669	£138,107	£6,794,068	£15,325,000



Reserves


Reserve	Current Month £'000	Month 5 £'000	Movement £'000	
Cost Pressure	3,130	3,166	(36)	Includes funding into budgets for ePrescribing £4.4k Community Cost Pressures £14.4k, FT Costs £15.5k and Appointment O/Time DNA Health Records £1.7k.
Activity and Developments	1,636	1,844	(209)	Includes income into reserves for CVO NHS Worcestershire £37k, Lucentis £126k and WMAS Anticipated income £4.7k. Less funding into budgets for Robotic Surgery £7.6k, Trauma & Orthopaedics £48k, A&E Expansion £30k, Healthy Lifestyles CVO £184k, IMRT Business Case £6.6k, Revised Brachytherapy £27k, Trauma & Orthopaedics Non Recurring Business Case £7.6k, Electrophysiology £8.5k, Materials Management £9k, Stent Anticipated Income £21k, ICD Anticipated Income £27k.
Quality	585	658	(73)	Includes funding into budgets for the Safety Alert £20k, Intravenous BC £36.4k and Surgical Site £16.3k.
Drugs and Devices	800	892	(91)	Includes income into reserves for Excluded Drugs £198.6k, Step Down Beds £4.9k and ICDF Drugs £33k. Less funding into budgets for Drugs Growth £296k and Insulin Pumps £31k.
Non Recurrent Support	2,995	3,265	(271)	Includes funding into budgets for Locum and Agency costs £33.3k, Health Records £9k, Equal Pay Settlement £1k, Reablement Funding £12.5k, Cough Check £10.5k, Interim COO £9.3k, CVO Palliative Care £5.4k, Integrated Electronic Patient Record Business Case £7k, MARS Payments £138k, 7 Day Working £41.3k and Mgt Accounts Projects Post £3.9k.
	9,146	9,825	(679)	
Inflation and Contingency	3,065	3,078	(13)	Includes income into reserves for Procurement £26k. Less funding into budgets for Energy £36.8k and JMS Flex Trainees/Contract Adj £2k.
Patient Activity Contingency	4,000	4,000	0	
Grand Total Reserves	16,211	16,904	(692)	

Capital Expenditure

The Trust Capital Programme for 2012/13 is £23,454k, excluding PFI (Radiology) additions. Capital Resource Limit (CRL) is likely to be set at the Plan level submitted to the SHA of £25,195k. This includes £2,541k for PFI less £800k due to assumed funding being available with the sale of the Old Eye Infirmary. Formal notification has been received for £22,654k; CRL for PFI will follow later in the year.

The Head of Estates Development Report to the Board provides further information regarding the capital underspend against plan to date and notes that a number of schemes are being considered for inclusion in a Revised Capital Programme to be agreed during October 2012. On this basis, no risk is currently envisaged in achieving the CRL planned expenditure position.

Capital Plan vs Capital Expenditure 2012/13 (Cumulative)




At the end of September 2012 Capital Spend was 80% on target with spend of £9.7m (million) against plan of £12.2m. The £2.5m underspend is mainly due to the previously reported re-profile of capital spend on the Combined Heat and Power (CHP) Scheme, with £1m underspend to date against the original plan. The project will now be completed by December 2012; two months later than original plan. Other more significant underspend to date include:- Medical Equipment and IT £0.4m; Improvement of Retained Estate £0.3m; and Poplars £0.3m. As noted above, with the action being taken in October, there is not currently any risk being identified against achieving the CRL.

Capital Expenditure by Scheme

The Capital programme is managed on a project by project basis by the Capital Division within the Estates Development Department. The chart below details actual vs. planned expenditure per the Capital Programme categories and, within those categories, schemes of significant value.

Actual YTD vs Plan YTD Capital Expenditure (£000)



Statement of Financial Position as at 30th September 2012

Trade and Other Receivables as at 30 September 2012 are £11,892 a breakdown is provided on page 29.

This includes invoiced NHS £2,316k and gross Non-NHS £896k receivables. A more detailed analysis of the invoiced receivables is shown on page 30.

Calculated debtor days for the year to date are 5.25 days compared to a plan of 8.16 days.

A more detailed analysis of Trade & Other Payables is provided on page 31.

The Public Sector Payment Policy sets out a target for payment of 95%, in value and volume, to be paid within 30 days of receipt. The Trust's cumulative performance against this target is:

- Value 93 %
- Volume 87 %

	<u>September</u> <u>2012 Plan</u> <u>£000</u>	<u>September</u> <u>2012 Actual</u> <u>£000</u>	<u>August 2012</u> <u>Actual £000</u>	<u>Movement in</u> <u>Month £000</u>	<u>March 2012</u> <u>Actual £000</u>
NON CURRENT ASSETS					
Property, Plant and Equipment	256,605	253,703	252,845	858	251,189
Intangible Assets	0	597	622	(25)	746
Other Non Current Assets	1,491	1,916	1,916	0	1,916
TOTAL NON CURRENT ASSETS	258,096	256,216	255,383	833	253,851
CURRENT ASSETS					
Inventories	5,703	4,896	5,144	(248)	5,703
Trade and Other Receivables	11,314	11,892	12,346	(454)	18,780
Cash and cash equivalents	16,700	16,635	22,531	(5,896)	15,658
TOTAL CURRENT ASSETS	33,717	33,423	40,021	(6,598)	40,141
Non Current Assets Held for Sale	800	800	800	0	800
TOTAL ASSETS	292,613	290,439	296,204	(5,765)	294,792
CURRENT LIABILITES					
Trade & Other Payables	(29,988)	(28,265)	(34,288)	6,023	(34,016)
Borrowings	(1,720)	(1,830)	(1,844)	14	(1,844)
Provisions for Liabilities and Charges	(3,193)	(3,042)	(3,042)	0	(3,193)
TOTAL CURRENT LIABILITIES	(34,901)	(33,137)	(39,174)	6,037	(39,053)
NET CURRENT ASSETS / (LIABILITIES)	(1,184)	286	847	(561)	1,088
TOTAL ASSETS LESS CURRENT LIABILITIES	257,712	257,302	257,030	272	255,739
NON CURRENT LIABILITIES					
Other Liabilities	(7,229)	(7,171)	(7,310)	139	(8,085)
Provision for Liabilities and Charges	(457)	(457)	(457)	0	(457)
TOTAL NON CURRENT LIABILITIES	(7,686)	(7,628)	(7,767)	139	(8,542)
TOTAL ASSETS EMPLOYED	250,026	249,674	249,263	411	247,196
FINANCED BY TAXPAYERS EQUITY					
Public Dividend Capital	170,082	170,082	170,082	0	170,082
Retained Earnings	10,724	10,373	9,962	411	7,894
Revaluation Reserve	69,030	69,029	69,029	0	69,030
Other Reserves	190	190	190	0	190
TOTAL TAXPAYERS EQUITY	250,026	249,674	249,263	411	247,196

Trade Receivables

<u>Trade & Other Receivables</u>	<u>September</u>	<u>August Movement</u>		
	<u>£000</u>	<u>£000</u>	<u>£000</u>	<u>%</u>
NHS Receivables - Revenue	2,316	2,966	(650)	-21.9%
NHS Partially Completed Spells	1,633	1,438	195	13.6%
NHS Accrued Income	3,142	2,760	382	13.8%
Non NHS Sales Ledger	896	1,036	(140)	-13.5%
Provision for Impairments of Receivables	(477)	(526)	49	-9.3%
TCS Receivables & Prepayments	75	75	0	0.0%
Non NHS Accrued Income	1,024	981	43	4.4%
Prepayments	1,683	2,024	(341)	-16.8%
RTA / Injury Claims due within 1 year	1,197	1,210	(13)	-1.1%
VAT	243	250	(7)	-2.8%
Other	160	132	28	21.2%
Total Trade & Other Receivables	11,892	12,346	(454)	-3.7%

- Further analysis of NHS and Non NHS Sales Ledger Receivables is provided on page 30.
- The increase in NHS Accrued Income mainly relates to over performance on patient activity contracts, this is currently being negotiated with the host Wolverhampton Commissioners to enable invoices to be raised for settlement.

Receivables by Category

The overall debt position has decreased by £0.8m in month.

In month, Wolverhampton City PCT settled £0.7m of older debt, of which £0.4m related to debt over 3 months old. BEN PCT paid £0.4m of which £0.2m related to debt between 2-3 months old. With the changes in NHS structures Finance are working pro-actively with NHS Shared Business Services to clear PCT debt.

Private Patient debt outstanding for over 3 months relates to invoices to insurance companies not yet settled. This includes 5 invoices totalling £144k. Of this outstanding debt £10k has been paid in October and a further £25k has been agreed to be paid by the end of the month. The Trust is working on resolving the other outstanding issues. These have been provided for by the Trust.

September 2012

Customer Type	Customer Type	Total Balances due	Within Term	Over Term 0-1 Months	Over Term 1-2 Months	Over Term 2-3 Months	Over Term >3 Months
		£'000	£'000	£'000	£'000	£'000	£'000
NHS	OTHER	286	194	27	17	38	10
	PCT	1,359	568	394	124	27	246
	SHA	43	28	0	0	15	0
	TRUST	628	525	20	48	14	21
NHS Total		2,316	1,315	441	189	94	277
NON	OTHER	310	119	107	64	0	20
	PRIVATE PATIENTS	458	46	102	78	6	226
	IRISH/SCOTT/WELSH	128	32	29	34	0	33
	Sub Total	896	197	238	176	6	279
	Bad Debt Provision	-285				-6	-279
NON Total		611	197	238	176	0	0
Grand Total		2,927	1,512	679	365	94	277

Older Trust debt decreased with Mid Staffordshire FT settling £0.1m of debt between 0-2 months and Walsall Healthcare NHS Trust settling £0.1m.

August 2012

Customer Type	Customer Type	Total Balances due	Within Term	Over Term 0-1 Months	Over Term 1-2 Months	Over Term 2-3 Months	Over Term >3 Months
		£'000	£'000	£'000	£'000	£'000	£'000
NHS	OTHER	225	63	90	57	0	15
	PCT	2,279	975	521	177	184	422
	SHA	15	0	15	0	0	0
	TRUST	446	91	281	46	13	15
NHS Total		2,965	1,129	907	280	197	452
NON	OTHER	399	195	121	3	3	77
	PRIVATE PATIENTS	533	212	79	6	5	231
	IRISH/SCOTT/WELSH	110	35	45	0	2	28
	Sub Total	1,042	442	245	9	10	336
	Bad Debt Provision	-346				-10	-336
NON Total		696	442	245	9	0	0
Grand Total		3,661	1,571	1,152	289	197	452

Of older Non NHS debt agreed to date to be settled in October, this relates to:- Other debt of between 1-2 months of circa £0.04m and Non NHS Irish/Scottish and Welsh debt between 1-2 months, circa £0.03m.


Trade & Other Payables

<u>Trade & Other Payables</u>	<u>September</u>	<u>August</u>	<u>Movement</u>	
	<u>£000</u>	<u>£000</u>	<u>£000</u>	<u>%</u>
NHS Payables - Revenue	(903)	(1,056)	153	-14.5%
Non NHS Trade Payables - Revenue	(2,194)	(3,277)	1,083	-33.0%
Non NHS Trade Payables - Capital	(3,788)	(3,178)	(610)	19.2%
Dividend and Interest Accrual	0	(3,383)	3,383	-100.0%
Tax & Social Security	(4,826)	(4,876)	50	-1.0%
Pensions	(2,937)	(2,921)	(16)	0.5%
Accruals	(8,609)	(9,564)	955	-10.0%
Deferred Income (inc. Trading Accounts)	(4,758)	(5,709)	951	-16.7%
Other	(250)	(324)	74	-22.8%
Total Trade & Other Payables	(28,265)	(34,288)	6,023	-17.6%

- Payables have decreased with settlement of issues with some suppliers relating to older debt.
- The decrease in Dividend Accrual relates to the settlement of the half year sum due. PDC Dividend is settled twice yearly, the next payment will be due in March 2013.
- The main element of the Deferred Income decrease relates to the release of September training income as the Strategic Health Authority provided the second quarters income in advance.

Cash Flow Statement - period ending 30th September 2012

	September Plan £000	September Actual £000	September Variance £000
OPERATING ACTIVITIES			
Total Operating Surplus/(Deficit)	7,418	7,268	(150)
Depreciation	7,526	7,344	(182)
Fixed Asset Impairments	0	0	0
Transfer from Donated Asset Reserve	0	0	0
Interest Paid	(756)	(771)	(15)
Dividends Paid	(4,066)	(4,067)	(1)
(Increase)/Decrease in Inventories	0	806	806
(Increase)/Decrease in Trade/Receivables	7,892	6,887	(1,005)
Increase/(Decrease) in Trade/Payables	(3,948)	(5,900)	(1,952)
Increase/(Decrease) in Provisions	0	(151)	(151)
NET CASH INFLOW/(OUTFLOW) FROM OPERATING ACTIVITIES	14,066	11,416	(2,650)
CASH FLOWS FROM INVESTING ACTIVITIES			
Interest Received	36	50	14
Payment for Property, Plant and Equipment	(12,196)	(9,412)	2,784
Payment for Intangible Assets	0	(149)	(149)
Payment for Other Assets	0	0	0
Proceeds from Disposals	0	0	0
NET CASH INFLOW/(OUTFLOW) FROM INVESTING ACTIVITIES	(12,160)	(9,511)	2,649
NET CASH INFLOW/(OUTFLOW) BEFORE FINANCING	1,906	1,905	(1)
FINANCING			
Capital Element of Finance Lease and PFI	(864)	(928)	(64)
NET CASH INFLOW/(OUTFLOW) FROM FINANCING	(864)	(928)	(64)
INCREASE/(DECREASE) IN CASH	1,042	977	(65)
CASH BALANCES			
Opening Balance 1st April 2012	15,658	15,658	0
Closing Balance at 30 September 2012	16,700	16,635	(65)



Cash against Plan

- The cash balance of £16.6m is in line with plan.
- However, there is a cash underspend on capital compared to plan. This has been offset by a higher level of NHS patient activity debt, relating to over performance against contracted activity levels, and a lower level of creditors than expected at the end of September.
- The cash balance has reduced by circa £6m in month, mainly due to the planned half yearly settlement of PDC dividend.

Charitable Funds for Period Ending 30th September 2012

The table below shows Summary Information relating to the movement in the Royal Wolverhampton NHS Trust Charity Funds for the period ended 30th September 2012. The more significant spend and income items have been detailed.

Q1 Information					Q2 Information					
Opening balance 31 March 2012	Donations	Investment Income	Expenditure	Closing Balance 30 June 2012	Opening balance 30 June 2012	Donations	Investment Income	Expenditure	Loss on Investments	Closing Balance 30 September 2012
£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
2,908	67	11	(42)	2,944	2,944	126	19	(114)	(50)	2,925

Main Donations include:-

- Ophthalmology £8k,
 - A&E £5k
 - Orthopaedics £5k
- And includes Legacies:-
- Care of Elderly £16k
 - WEI £6k.

The more significant spend items are:-

- Breast feeding chairs £3k
- Other equipment for Neonatal £2k
- Tablet PCs for Breast Care £6k
- Specialised spinal instruments in Orthopaedics £6k
- Royal awards £12k

Includes Donations for :-

- Care of the Elderly £29k
 - Breast Care £14k
 - Deanesly £10k
- And includes Legacies:-
- Deanesly £6k

The main areas of spend are:-

- Neo-natal unit blankets £11k,
- Cardiothoracic Thoroscopic Equipment £8k,
- Paediatric Cystic Fibrosis Vest £3k